Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1401 results for 0

  1. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575

  2. Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)

    Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA893

  3. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  4. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  5. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

    Medtech innovation briefing
    Published
    28 February 2019

  6. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued Reference number: GID-TA10395

    Technology appraisal guidance
    Discontinued

  7. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  8. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  9. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

    Technology appraisal guidance
    Published
    23 July 2008
    View recommendations

    Sections for TA151

  10. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA75

  11. Deep brain stimulation for Parkinson's disease (HTG7)

    Evidence-based recommendations on deep brain stimulation for Parkinson's disease. This involves planting electrodes into the brain and generating electrical currents to reduce the problems caused by Parkinson's disease.

    HealthTech guidance
    Published
    26 November 2003
    View recommendations

    Sections for HTG7

  12. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (HTG282)

    Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.

    HealthTech guidance
    Last updated
    19 July 2022
    View recommendations

    Sections for HTG282

  13. ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)

    NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .

    Medtech innovation briefing
    Published
    10 May 2022

  14. CareLink network service for remote monitoring of people with cardiac devices (MIB64)

    NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices

    Medtech innovation briefing
    Published
    24 May 2016

  15. MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

    HealthTech guidance
    Published
    24 May 2023
    View recommendations

    Sections for HTG678